Validation of the “Patient‐Acceptable Symptom State” Question as Outcome Measure in AChR Myasthenia Gravis: A Multicentre, Prospective Study
European Journal of Neurology · 2025-06 · 32 (6)
DOI: 10.1111/ene.70262 ↗At a glance
Multizentrische Studie in European Journal of Neurology, published online on 2025-06-25. Written by Gregorio Spagni and 10 co-authors. Institution: Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy. Major MEDLINE topics: Myasthenia Gravis, Patient Reported Outcome Measures. Cited 7 times so far (Crossref); 15 references. The full text is freely available (open access, CC BY 4.0). Funded by: NCATS NIH HHS, the Myasthenia Gravis Rare Disease Network-MGNet, NIHR Academic Clinical Lectureship.
Abstract (original language)
Introduction
Patient Acceptable Symptom State (PASS) is emerging as a valuable subjective measure of the overall myasthenia gravis (MG)‐related burden. This study aimed at identifying PASS‐positive thresholds for the most used clinical scales, investigating whether PASS and MGFA post‐intervention status capture different aspects of the disease outcome, and identifying clinical variables associated with PASS=YES response.
Methods
Adult AChR‐MG patients were prospectively enrolled at two Italian Centres (Rome: index cohort; Florence: validation cohort). PASS thresholds for MG‐ADL, QMG, and MG‐QOL15r were defined in the index cohort by ROC analysis and validated in the validation cohort; predictors of favorable PASS were identified by multivariable analysis.
Results
This study included 173 patients (44% females, median age at onset: 53 years). PASS=YES patients had significantly lower median MG‐ADL, QMG, and MG‐QOL15r scores, with the following thresholds for PASS=YES: MG ADL ≤ 2, QMG ≤ 8 and MG‐QOL15r ≤ 6. The MG‐ADL (OR = 0.46, 95% CI = 0.36–0.60, p < 0.001), QMG (OR = 0.72, 95% CI = 0.64–0.81, p < 0.001) and MG‐QOL15r (OR = 0.76, 95% CI = 0.70–0.84, p < 0.001), were independently associated with a favorable PASS. The degree of ocular involvement in each scale was the strongest negative determinant of PASS=YES.
Conclusions
This study validates the PASS question and highlights the relevance of ocular complaints in patients' perception of MG burden.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy.
- Department of Neurosciences and Sensory Organs, Careggi University Hospital, Florence, Italy.
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
- Department of Neurosciences, Catholic University of the Sacred Hearth, Rome, Italy.
ORCID profiles: Gregorio Spagni, Amelia Evoli
Funding
- NCATS NIH HHS
- the Myasthenia Gravis Rare Disease Network-MGNet
- NIHR Academic Clinical Lectureship
- Ministero dell'Istruzione, dell'Università e della Ricerca
- Italian Ministry of Health
- NINDS NIH HHS
- Ministero della Salute
Cite
APA
Spagni, G., Verza, M. U., Cornacchini, S., Beretta, F., Sun, B., Lotti, A., Falso, S., Barilaro, A., Massacesi, L., Evoli, A., & Damato, V. (2025). Validation of the “Patient‐Acceptable Symptom State” Question as Outcome Measure in AChR Myasthenia Gravis: A Multicentre, Prospective Study. European Journal of Neurology, 32(6). https://doi.org/10.1111/ene.70262
Vancouver
Spagni G, Verza MU, Cornacchini S, Beretta F, Sun B, Lotti A, et al. Validation of the “Patient‐Acceptable Symptom State” Question as Outcome Measure in AChR Myasthenia Gravis: A Multicentre, Prospective Study. European Journal of Neurology. 2025;32(6). doi:10.1111/ene.70262
BibTeX
@article{Spagni2025,
author = {Spagni, Gregorio and Verza, Massimiliano Ugo and Cornacchini, Sara and Beretta, Francesca and Sun, Bo and Lotti, Antonio and Falso, Silvia and Barilaro, Alessandro and Massacesi, Luca and Evoli, Amelia and Damato, Valentina},
title = {Validation of the “Patient‐Acceptable Symptom State” Question as Outcome Measure in AChR Myasthenia Gravis: A Multicentre, Prospective Study},
journal = {European Journal of Neurology},
year = {2025},
volume = {32},
number = {6},
doi = {10.1111/ene.70262}
}
EUVIMED